Pharming announces updated 2023 guidance and expects 10% growth in Ruconest revenue
Pharming Group announces updated full year 2023 guidance and expects 10% growth in Ruconest revenue, significantly exceeding prior guidance Pharming Group announces updated full year 2023 guidance, including Ruconest revenues. For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*). Sijmen de Vries, Chief [...]